PDCD1 and head and neck squamous cell carcinoma: <b>Introduction:</b> T cell checkpoint inhibitors targeting Programmed cell Death protein-1 (PD-1) have emerged as novel immunotherapy agents showing remarkable efficacy in head and neck squamous cell carcinoma (HNSCC).